Effects of Digital Stories Intervention on Psychosocial Well-being
2 other identifiers
interventional
202
1 country
1
Brief Summary
Patients and caregivers undergoing hematopoietic stem cell transplantation often continue to experience anxiety, depression, isolation, and other psychosocial distress. A narrative-based digital stories intervention has shown promise in a pilot study with breast cancer patients in helping to alleviate emotional distress. This study is designed to test digital stories to be viewed and discussed by other HCT patients/caregivers as a psychosocial intervention in a randomized controlled trial and to test the effects of digital stories on how 110 patient and caregiver dyads (N=220) undergoing one of the most rigorous and aggressive treatments cope with treatment-related distress through supportive open dyadic communication and emotional expression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2017
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2017
CompletedFirst Submitted
Initial submission to the registry
August 27, 2018
CompletedFirst Posted
Study publicly available on registry
August 31, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 5, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
July 23, 2021
CompletedResults Posted
Study results publicly available
October 9, 2024
CompletedOctober 9, 2024
October 1, 2024
3.3 years
August 27, 2018
May 8, 2023
October 1, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes From Baseline Profile of Mood States (POMS) Short Version (Emotional Well-being or /Reduction of Emotional Distress) at 4 Weeks
Emotional Well-Being (Reduction of Emotional Distress) will be measured using the Profile of Mood States (POMS) short version (15 items, 5-point Likert scale; 0=not at all, 4=extremely). The POMS is one of the most frequently used and validated scales in studies of psychosocial interventions for cancer patients. The POMS Total Mood Disturbance (TMD) score has been shown to be most sensitive to interventions designed to facilitate emotional expression.The POMS consists of the TMD dimensions (tension-anxiety; depression-dejection; anger-hostility; and confusion-bewilderment) (Cronbach's a = .93) to be used in the current study as the primary outcome measure; and two others (fatigue-inertia; vigor-activity) will be documented. Total of Mood Disturbance= (anxious+depression+anger+fatigue)- vigor (Range from 12 to 48). The higher values represent a worse emotional well-being.
Baseline (T1), T2 (after 4-week intervention)
Secondary Outcomes (1)
Changes From Baseline Emotional Well-being (Using the Emotional Acceptance Scale) at 4 Weeks
Baseline (T1), T2 (after 4-week intervention)
Study Arms (4)
Baseline and Digital Stories (DS) for patients
EXPERIMENTALIn-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
Baseline and Information Control (IC) for patients
ACTIVE COMPARATORIn-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
Baseline and Digital Stories (DS) for caregivers
EXPERIMENTALIn-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture before the random assignment to DS arm. Eight Digital Stories Intervention (4 patient and 4 caregiver stories about hematopoietic stem cell transplantation (HCT) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call. Each story was made with voice, images, and sound (3-5 minutes each).
Baseline and Information Control (IC) for caregivers
ACTIVE COMPARATORIn-person baseline surveys using the web-based data collection platform, Research Electronic Data Capture (REDCap) before the random assignment to IC arm. Eight Information Control Intervention videos containing only information about post-HCT care (as opposed to story/narrative) over the course of 4 weeks (2 videos per week) with a weekly email notification and reminder phone call.
Interventions
Baseline surveys contained a series of scaled questions, including sociodemographic variables (age, sex, cancer type, and etc), profile of mood states, social well-being, emotional processing and acceptance.
Digital Stories Intervention Videos contain the following content: caregiver burden, positive and cognitive coping, support from other family and friends, fear of losing the patient, spirituality, guilt of being sick, and expressing emotions/feelings
Information Control Intervention Videos include Information about post-HCT. The topics in the IC include specific guidelines to return to wellness post HCT through (1) an exercise plan, (2) a nutrition (dietary) plan, (3) pain management, (4) information about the complications, (5) caregiver responsibilities, (6) social support, (7) preventing from infections, and (8) symptom management. Participants randomized to the IC will receive the full set of DS modules only after the final 3-month post-intervention data collection point has passed and they can view them as desired.
Eligibility Criteria
You may qualify if:
- age 18 or older
- recently underwent Hematopoietic cell transplantation (HCT) (within a month after hospital discharge)
- must be able to speak, read, and write in English
- access to a working phone and e-mail account
You may not qualify if:
- no primary caregiver
- cognitive impairment that prohibits completion of study assessment
- visual or hearing impairment
- other (e.g., provider non-approval or logistical constraints such as patient moving out of town)
- age 18 or older
- family caregivers who are identified as a primary caregiver by a patient
- have primary responsibility for the care of patients throughout the HCT process
- Must be able to speak, read, and write in English
- Access to a working phone and e-mail account
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Arizona State Universitylead
- Mayo Cliniccollaborator
- National Cancer Institute (NCI)collaborator
Study Sites (1)
Mayo Clinic
Phoenix, Arizona, 85054, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Sunny Kim
- Organization
- Arizona State University
Study Officials
- PRINCIPAL INVESTIGATOR
Sunny Kim, Ph.D
Arizona State University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 27, 2018
First Posted
August 31, 2018
Study Start
September 1, 2017
Primary Completion
January 5, 2021
Study Completion
July 23, 2021
Last Updated
October 9, 2024
Results First Posted
October 9, 2024
Record last verified: 2024-10
Data Sharing
- IPD Sharing
- Will not share